Contract research organisation and drug discovery business Metrion Biosciences has established a scientific advisory board, which will provide strategic scientific guidance to the company.
The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.
Dr Reynolds has served in numerous positions at Merck, Lundbeck and Pfizer.
Dr Tom Colatsky also joins the board following over 30 years of drug discovery experience, including seven years in senior US Food and Drug Admistration positions.
The board will also comprise of Professor Annette Dolphin, Professor Chris Denning and Marc Rogers, who is currently chief scientific officer at Metrion.